No :) I’m saying that the epitope the ligand binds may have bioactive analogs on other proteins in sites accessible to the ligand. This is where off-target binding mostly comes from, and it’s hard to prevent.
Contrast this with a ligand being good at “binding things in general,” ie without regard to structure. This problem is relatively easy to prevent.
No :) I’m saying that the epitope the ligand binds may have bioactive analogs on other proteins in sites accessible to the ligand. This is where off-target binding mostly comes from, and it’s hard to prevent.
Contrast this with a ligand being good at “binding things in general,” ie without regard to structure. This problem is relatively easy to prevent.